v3.26.1
Summary of Significant Accounting Policies - Summary of Selected Financial Information with Respect to Operating Segment (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]    
License revenue   $ 167,500,000
Research and development expenses    
Personnel-related costs $ 45,758,000 34,548,000
Clinical trial expenses 18,467,000 10,511,000
Outside research and development services 16,783,000 14,458,000
Manufacturing expenses 6,308,000 3,606,000
Facilities, depreciation, and other expenses 21,132,000 20,373,000
Total research and development expenses 108,448,000 83,496,000
General and administrative expenses 34,451,000 26,418,000
Total operating expenses 142,899,000 109,914,000
(Loss) income from operations (142,899,000) 57,586,000
Segment interest and other income, net 11,779,000 4,654,000
Change in fair value of convertible promissory notes 0 (8,837,000)
(Loss) income before income tax expense $ (131,120,000) $ 53,403,000